Welcome to our dedicated page for 4D Molecular Therapeutics SEC filings (Ticker: FDMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) SEC filings page provides access to the company’s regulatory disclosures as a public issuer. These documents include current reports on Form 8-K, periodic reports and other filings that describe clinical progress, material agreements, capital raises, governance changes and stockholder actions.
For investors tracking 4D Molecular Therapeutics’ gene therapy programs, Form 8-K filings are particularly relevant. Recent 8-Ks have covered topics such as interim clinical data from the PRISM Phase 1/2 trial of 4D-150 in wet age-related macular degeneration, updates on the AEROW trial of 4D-710 in cystic fibrosis lung disease, the collaboration and license agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets, and the appointment or transition of key executives and directors. Other 8-Ks report on equity offerings, preliminary cash and investment balances, and amendments to corporate bylaws.
Filings also disclose that 4D Molecular Therapeutics’ common stock trades on the Nasdaq Global Select Market under the symbol FDMT, and they provide details on matters submitted to stockholder votes, such as director elections, auditor ratification and advisory votes on executive compensation and its frequency.
On Stock Titan, these SEC filings are updated in near real time from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key terms of collaboration and license agreements, explain the implications of financing transactions, and surface important information about clinical data disclosures, governance changes and cash runway guidance. Users can also review filings that relate to equity offerings, including underwriting agreements and pre-funded warrants, and examine how these transactions fit into 4D Molecular Therapeutics’ overall development and funding strategy.
4D Molecular Therapeutics, Inc. files a shelf registration to register up to $400.0 million of securities, which includes $200.0 million of unsold securities previously registered and approximately $200.0 million of additional securities.
The prospectus covers multiple classes — common stock, preferred stock, debt securities, warrants and units — to be sold from time to time under a shelf process. The document is a preliminary prospectus dated May 7, 2026 and states that specific offering terms will be provided in prospectus supplements.
4D Molecular Therapeutics reported a larger net loss as it accelerated investment in its late-stage gene therapy pipeline for the three months ended March 31, 2026. Collaboration and license revenue rose to $3.0 million, primarily from its Otsuka partnership, while research and development spending increased to $65.0 million. The company posted a net loss of $68.8 million, compared with $48.0 million a year earlier, and ended the quarter with $457.6 million in cash, cash equivalents and marketable securities. Management believes this cash balance can fund planned operations for at least one year.
4D Molecular Therapeutics reported Q1 2026 results highlighted by advancing its lead eye disease program and maintaining a strong balance sheet. Collaboration and license revenue reached $3.0 million, while research and development expenses rose to $65.0 million as the company executed Phase 3 trials for 4D-150 in wet age-related macular degeneration.
General and administrative expenses were $11.7 million, and net loss was $68.8 million, or $1.01 per share. Cash, cash equivalents and marketable securities totaled $458 million as of March 31, 2026, which the company expects will fund operations into the second half of 2028. The 4FRONT-1 Phase 3 trial completed randomization of 523 patients, with topline data expected in the first half of 2027, and additional PRISM, SPECTRA and DME Phase 3 milestones are planned through 2026–2027.
4D Molecular Therapeutics is asking stockholders to vote at its all-virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class III directors, ratify PricewaterhouseCoopers as auditor for 2026, and cast a non-binding advisory vote on executive pay. Holders of 52,274,735 common shares as of April 20, 2026 may vote, with additional context of 16,935,665 shares issuable upon exercise of pre-funded warrants. The company details board structure, committee memberships, director compensation, and 2025 pay for named executives, including President and CEO David Kirn, M.D.
Janus Henderson Group plc amended a Schedule 13G to report beneficial ownership of 5,247,151 shares of 4D Molecular Therapeutics, Inc., representing 10.3% of the common stock as disclosed. The filing states the Asset Managers exercise shared voting and dispositive power over these shares and disclaim rights to dividends or sale proceeds tied to the Managed Portfolios. The amendment is signed on 04/07/2026 and the cover lists 03/31/2026 in the header.
4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company’s Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer.
Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer’s prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare.
4D Molecular Therapeutics granted Chief Executive Officer David Kirn a stock option covering 750,000 shares of common stock. The option has an exercise price of $9.88 per share and expires on March 24, 2036.
The award vests over four years, with 1/48 of the shares vesting monthly starting on March 25, 2026, so long as he continues as a service provider. Following this grant, the filing shows 750,000 derivative securities (options) held directly by Kirn.
4D Molecular Therapeutics reported a stock option grant to Chief Legal Officer Scott Bizily. The award covers 217,000 options for common stock at an exercise price of $9.88 per share and expires on March 24, 2036.
The options vest in equal monthly installments over four years, with 1/48th of the underlying shares vesting on each monthly anniversary of March 25, 2026, so long as Bizily remains a service provider. This is a compensation-related equity grant, not an open-market share purchase or sale.
4D Molecular Therapeutics, Inc. reported that officer Christopher Paul Simms received a grant of stock options covering 219,000 shares of common stock. The options have an exercise price of $9.88 per share and expire on March 24, 2036.
According to the terms, 1/48 of the underlying shares will vest each month starting on March 25, 2026, so long as Simms remains a service provider, with full vesting on the fourth anniversary of that date. Following this grant, he holds options for 219,000 shares directly.